<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">35907175</PMID><DateCompleted><Year>2022</Year><Month>09</Month><Day>19</Day></DateCompleted><DateRevised><Year>2022</Year><Month>12</Month><Day>22</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1179-1934</ISSN><JournalIssue CitedMedium="Internet"><Volume>36</Volume><Issue>9</Issue><PubDate><Year>2022</Year><Month>Sep</Month></PubDate></JournalIssue><Title>CNS drugs</Title><ISOAbbreviation>CNS Drugs</ISOAbbreviation></Journal><ArticleTitle>Sodium Phenylbutyrate and Ursodoxicoltaurine: First Approval.</ArticleTitle><Pagination><StartPage>1007</StartPage><EndPage>1013</EndPage><MedlinePgn>1007-1013</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s40263-022-00945-x</ELocationID><Abstract><AbstractText>An oral, fixed-dose coformulation of sodium phenylbutyrate and ursodoxicoltaurine (ALBRIOZA<sup>&#x2122;</sup>; hereafter denoted sodium phenylbutyrate/ursodoxicoltaurine) is being developed by Amylyx Pharmaceuticals for the treatment of neurodegenerative diseases. In June 2022, the coformulation received its first approval with conditions in Canada for the treatment of amyotrophic lateral sclerosis (ALS) in adults. The approval was based on results from the multicentre, phase II CENTAUR trial, in which slowing of ALS progression was demonstrated with sodium phenylbutyrate/ursodoxicoltaurine relative to placebo. This article summarizes the milestones in the development of sodium phenylbutyrate/ursodoxicoltaurine leading to this first approval.</AbstractText><CopyrightInformation>&#xa9; 2022. The Author(s), under exclusive licence to Springer Nature Switzerland AG.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Heo</LastName><ForeName>Young-A</ForeName><Initials>YA</Initials><AffiliationInfo><Affiliation>Springer Nature, Mairangi Bay, Private Bag 65901, Auckland, 0754, New Zealand. cns@adis.com.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>figshare</DataBankName><AccessionNumberList><AccessionNumber>10.6084/m9.figshare.20327265</AccessionNumber></AccessionNumberList></DataBank></DataBankList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>New Zealand</Country><MedlineTA>CNS Drugs</MedlineTA><NlmUniqueID>9431220</NlmUniqueID><ISSNLinking>1172-7047</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004364">Pharmaceutical Preparations</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010654">Phenylbutyrates</NameOfSubstance></Chemical><Chemical><RegistryNumber>516-35-8</RegistryNumber><NameOfSubstance UI="D013655">Taurochenodeoxycholic Acid</NameOfSubstance></Chemical><Chemical><RegistryNumber>60EUX8MN5X</RegistryNumber><NameOfSubstance UI="C031655">ursodoxicoltaurine</NameOfSubstance></Chemical><Chemical><RegistryNumber>7WY7YBI87E</RegistryNumber><NameOfSubstance UI="C075773">4-phenylbutyric acid</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004364" MajorTopicYN="N">Pharmaceutical Preparations</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010654" MajorTopicYN="N">Phenylbutyrates</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013655" MajorTopicYN="N">Taurochenodeoxycholic Acid</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>7</Month><Day>31</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>9</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>7</Month><Day>30</Day><Hour>11</Hour><Minute>20</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35907175</ArticleId><ArticleId IdType="doi">10.1007/s40263-022-00945-x</ArticleId><ArticleId IdType="pii">10.1007/s40263-022-00945-x</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Brown RH, Al-Chalabi A. Amyotrophic lateral sclerosis. N Engl J Med. 2017;377(2):162&#x2013;72.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMra1603471</ArticleId></ArticleIdList></Reference><Reference><Citation>Hardiman O, Al-Chalabi A, Chio A, et al. Amyotrophic lateral sclerosis. Nat Rev Dis Primers. 2017;3:17085.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrdp.2017.85</ArticleId></ArticleIdList></Reference><Reference><Citation>Amylyx Pharmaceuticals Inc. Amylyx Pharmaceuticals announces Health Canada approval of ALBRIOZA&#x2122; for the treatment of ALS [media release]. 13 June 2022. http://www.amylyx.com .</Citation></Reference><Reference><Citation>Amylyx Pharmaceuticals Inc. ALBRIOZA sodium phenylbutyrate and ursodoxicoltaurine powder for suspension powder for suspension, 3g /1g sachet, oral. 2022. https://health-products.canada.ca/ . Accessed 16 July 2022.</Citation></Reference><Reference><Citation>Amylyx Pharmaceuticals Inc. Amylyx announces support from the ALS Finding a Cure Foundation and the Cure Alzheimers Fund to bring a new treatment for amyotrophic lateral sclerosis to clinical trials [media release]. 17 Nov 2015. http://www.amylyx.com .</Citation></Reference><Reference><Citation>ALS Association, PR Newswire. The ALS Association and ALS Finding a Cure announce joint funding support for Amylyx clinical trial of AMX0035 for the treatment of ALS [media release]. 21 July 2016. http://www.amylyx.com .</Citation></Reference><Reference><Citation>Amylyx Pharmaceuticals Inc. Amylyx announces $5 million series A financing to support phase II clinical trial of AMX0035 for treatment of amyotrophic lateral sclerosis [media release]. 23 Aug 2016. http://www.amylyx.com .</Citation></Reference><Reference><Citation>Alzheimer's drug discovery foundation. Innovative Alzheimer's disease combination therapy trial supported by new joint funding initiative [media release]. 25 Oct 2017. http://www.amylyx.com .</Citation></Reference><Reference><Citation>Amylyx Pharmaceuticals Inc. Amylyx Pharmaceuticals raises $30 Million in Series B funding [media release]. 1 July 2020. http://www.amylyx.com .</Citation></Reference><Reference><Citation>Amylyx Pharmaceuticals Inc. Amylyx Pharmaceuticals closes $135M Series C financing Led by Viking Global Investors to support late stage development of lead product candidate AMX0035 for the treatment of ALS [media release]. 20 July 2021. http://www.amylyx.com .</Citation></Reference><Reference><Citation>Fels JA, Dash J, Leslie K, et al. Effects of the investigational drug sodium phenylbutyrate-TUDCA (AMX0035) on the transcriptional and metabolic landscape of sporadic ALS fibroblasts. bioRxiv. 2022. https://doi.org/10.1101/2022.05.02.490306 .</Citation></Reference><Reference><Citation>Khalaf K, Tornese P, Cocco A, et al. Tauroursodeoxycholic acid: a potential therapeutic tool in neurodegenerative diseases. Transl Neurodegener. 2022;11(1):33.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40035-022-00307-z</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun Y, Bedlack R, Armon C, et al. ALSUntangled #64: butyrates. Amyotroph Lateral Scler Frontotemporal Degener. 2022. https://doi.org/10.1080/21678421.2022.2045323 .</Citation></Reference><Reference><Citation>Arnold SE, Hendrix S, Nicodemus-Johnson J, et al. Safety and biological activity of a fixed-dose coformulation of sodium phenylbutyrate and taurursodiol (PB/TURSO) for the treatment of alzheimer&#x2019;s disease: results from the phase 2a PEGASUS study [abstract no. LP15]. J Prev Alzheimers Dis. 2021;8(Suppl 1):S125&#x2013;6.</Citation></Reference><Reference><Citation>Paganoni S, Macklin EA, Hendrix S, et al. Trial of sodium phenylbutyrate-taurursodiol for amyotrophic lateral sclerosis. N Engl J Med. 2020;383(10):919&#x2013;30.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1916945</ArticleId></ArticleIdList></Reference><Reference><Citation>Paganoni S, Hendrix S, Dickson SP, et al. Effect of sodium phenylbutyrate/taurursodiol on tracheostomy/ventilation-free survival and hospitalisation in amyotrophic lateral sclerosis: long-term results from the CENTAUR trial. J Neurol Neurosurg Psychiatry. 2022. https://doi.org/10.1136/jnnp-2022-329024 .</Citation></Reference><Reference><Citation>Paganoni S, Watkins C, Cawson M, et al. Survival analyses from the CENTAUR trial in amyotrophic lateral sclerosis: evaluating the impact of treatment crossover on outcomes. Muscle Nerve. 2022. https://doi.org/10.1002/mus.27569 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mus.27569</ArticleId><ArticleId IdType="pubmed">35765222</ArticleId></ArticleIdList></Reference><Reference><Citation>Paganoni S, Hendrix S, Dickson S, et al. Long-term functional benefits and safety of a fixed-dose coformulation of sodium phenylbutyrate and taurursodiol in amyotrophic lateral sclerosis [abstract no. C3]. Amyotroph Lateral Scler Frontotemporal Degener. 2021;22(Suppl 2):2.</Citation></Reference><Reference><Citation>Paganoni S, Hendrix S, Dickson SP, et al. Long-term survival of participants in the CENTAUR trial of sodium phenylbutyrate-taurursodiol in amyotrophic lateral sclerosis. Muscle Nerve. 2021;63(1):31&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mus.27091</ArticleId></ArticleIdList></Reference><Reference><Citation>Amylyx Pharmaceuticals Inc. Amylyx Pharmaceuticals announces completion of enrollment in the PEGASUS trial of AMX0035 in Alzheimers disease [media release]. 16 June 2020. http://www.amylyx.com .</Citation></Reference><Reference><Citation>Amylyx Pharmaceuticals Inc. Amylyx Pharmaceuticals announces oral presentation of safety and tolerability data on AMX0035 from clinical trials at 2022 American Academy of Neurology annual meeting [media release]. 2 Apr 2022. http://www.amylyx.com .</Citation></Reference><Reference><Citation>Arnold SE, Paganoni S, Hendrix S, et al. Safety of a fixed-dose coformulation of sodium phenylbutyrate and taurursodiol in amyotrophic lateral sclerosis and Alzheimer&#x2019;s disease: integrated clinical trials experience [abstract no. S11.005]. Neurology. 2022;98(18 Suppl):131.</Citation></Reference><Reference><Citation>Van Den Berg L, Paganoni S, Van Eijk R, et al. Global phase 3, randomized, placebo-controlled trial of a fixeddose coformulation of sodium phenylbutyrate and taurursodiol in amyotrophic lateral sclerosis (A35&#x2013;004 PHOENIX): study design overview [abstract no. CLT-21]. Amyotroph Lateral Scler Frontotemporal Degener. 2021;22(Suppl 2):161&#x2013;2.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>